GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infinity Pharmaceuticals Inc (OTCPK:INFIQ) » Definitions » Beneish M-Score

Infinity Pharmaceuticals (Infinity Pharmaceuticals) Beneish M-Score : -3.12 (As of May. 05, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Infinity Pharmaceuticals Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.12 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Infinity Pharmaceuticals's Beneish M-Score or its related term are showing as below:

INFIQ' s Beneish M-Score Range Over the Past 10 Years
Min: -7.79   Med: -2.87   Max: 107.45
Current: -3.12

During the past 13 years, the highest Beneish M-Score of Infinity Pharmaceuticals was 107.45. The lowest was -7.79. And the median was -2.87.


Infinity Pharmaceuticals Beneish M-Score Historical Data

The historical data trend for Infinity Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infinity Pharmaceuticals Beneish M-Score Chart

Infinity Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.60 -4.07 -7.14 -2.61 -1.76

Infinity Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.40 -1.10 -1.76 -2.54 -3.12

Competitive Comparison of Infinity Pharmaceuticals's Beneish M-Score

For the Biotechnology subindustry, Infinity Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Infinity Pharmaceuticals's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infinity Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Infinity Pharmaceuticals's Beneish M-Score falls into.



Infinity Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Infinity Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1+0.528 * 0.9997+0.404 * 2.0555+0.892 * 1.1588+0.115 * 0.7127
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9663+4.679 * -0.157404-0.327 * 2.3475
=-3.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun23) TTM:Last Year (Jun22) TTM:
Total Receivables was $0.00 Mil.
Revenue was 0.583 + 0.731 + 0.543 + 0.712 = $2.57 Mil.
Gross Profit was 0.231 + 0.29 + 0.216 + 0.283 = $1.02 Mil.
Total Current Assets was $19.91 Mil.
Total Assets was $21.23 Mil.
Property, Plant and Equipment(Net PPE) was $1.08 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.43 Mil.
Selling, General, & Admin. Expense(SGA) was $15.99 Mil.
Total Current Liabilities was $12.06 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Net Income was -9.956 + -11.045 + -9.23 + -10.717 = $-40.95 Mil.
Non Operating Income was 0.209 + 0.507 + 0.353 + 0.209 = $1.28 Mil.
Cash Flow from Operations was -8.007 + -12.576 + -8.9 + -9.401 = $-38.88 Mil.
Total Receivables was $0.00 Mil.
Revenue was 0.686 + 0.652 + 0.451 + 0.428 = $2.22 Mil.
Gross Profit was 0.272 + 0.259 + 0.179 + 0.17 = $0.88 Mil.
Total Current Assets was $59.61 Mil.
Total Assets was $61.86 Mil.
Property, Plant and Equipment(Net PPE) was $1.90 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.48 Mil.
Selling, General, & Admin. Expense(SGA) was $14.28 Mil.
Total Current Liabilities was $14.34 Mil.
Long-Term Debt & Capital Lease Obligation was $0.63 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 2.569) / (0 / 2.217)
=0 / 0
=1

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.88 / 2.217) / (1.02 / 2.569)
=0.396933 / 0.397042
=0.9997

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (19.908 + 1.082) / 21.232) / (1 - (59.61 + 1.904) / 61.857)
=0.011398 / 0.005545
=2.0555

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2.569 / 2.217
=1.1588

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.482 / (0.482 + 1.904)) / (0.428 / (0.428 + 1.082))
=0.202012 / 0.283444
=0.7127

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(15.99 / 2.569) / (14.281 / 2.217)
=6.224212 / 6.441588
=0.9663

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 12.064) / 21.232) / ((0.633 + 14.339) / 61.857)
=0.568199 / 0.242042
=2.3475

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-40.948 - 1.278 - -38.884) / 21.232
=-0.157404

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Infinity Pharmaceuticals has a M-score of -3.12 suggests that the company is unlikely to be a manipulator.


Infinity Pharmaceuticals Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Infinity Pharmaceuticals's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Infinity Pharmaceuticals (Infinity Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1100 Massachusetts Avenue, Floor 4, Cambridge, MA, USA, 02138
Infinity Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products and those under development include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology related treatments. The company operates in only one segment which is drug development.
Executives
Adelene Q Perkins director, officer: President & CEO C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Stephane Peluso officer: Chief Scientific Officer 1100 MASSACHUSETTS AVENUE, CAMBRIDGE MA 02138
Brian Schwartz director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Robert Jr. Ilaria officer: Chief Medical Officer 1100 MASSACHUSETTS AVENUE, 4TH FLOOR, CAMBRIDGE MA 02138
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Richard Gaynor director C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
Jeffery Kutok officer: Chief Scientific Officer 784 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Samuel Agresta officer: Chief Medical Officer 784 MEMORIAL DR., CAMBRIDGE MA 02139
David W Beier director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Lawrence E Bloch officer: EVP, CFO & CBO
Michael Kauffman director C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Michael C Venuti director

Infinity Pharmaceuticals (Infinity Pharmaceuticals) Headlines

From GuruFocus